Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-05-15
2007-05-15
Aulakh, Charanjit S. (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S077000, C544S264000, C514S266400
Reexamination Certificate
active
10569303
ABSTRACT:
Compounds of structural formula I are modulators of the androgen receptor (AR) in a tissue selective manner. They are useful as agonists of the androgen receptor in bone and/or muscle tissue while antagonizing the AR in the prostate of a male patient or in the uterus of a female patient. These compounds are therefore useful in the enhancement of weakened muscle tone and the treatment of conditions caused by androgen deficiency or which can be ameliorated by androgen administration, including osteoporosis, osteopenia, glucocorticoid-induced osteoporosis, periodontal disease, bone fracture, bone damage following bone reconstructive surgery, sarcopenia, frailty, aging skin, male hypogonadism, postmenopausal symptoms in women, atherosclerosis, hypercholesterolemia, hyperlipidemia, obesity, aplastic anemia and other hematopoietic disorders, inflammatory arthritis and joint repair, HIV-wasting, prostate cancer, cancer cachexia, Alzheimer's disease, muscular dystrophies, cognitive impairment, decreased libido, premature ovarian failure, and autoimmune disease, alone or in combination with other active agents.
REFERENCES:
patent: 4377584 (1983-03-01), Rasmusson et al.
patent: 5237065 (1993-08-01), Holt et al.
patent: 5407939 (1995-04-01), Panzeri et al.
patent: 5418238 (1995-05-01), Panzeri et al.
patent: 5510351 (1996-04-01), Graham et al.
patent: 5525608 (1996-06-01), Adams et al.
patent: 5693809 (1997-12-01), Durette et al.
patent: 5710275 (1998-01-01), Bakshi et al.
patent: 6121449 (2000-09-01), Panzeri et al.
Meissner Robert S.
Mitchell Helen J.
Aulakh Charanjit S.
Daniel Mark R.
Merck & Co. , Inc.
Shatynski Patricia A.
LandOfFree
17-heterocyclic-4-azasteroid derivatives as androgen... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 17-heterocyclic-4-azasteroid derivatives as androgen..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 17-heterocyclic-4-azasteroid derivatives as androgen... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3809667